Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer
2585.2000 13.20 (0.51%)
NSE Sep 12, 2025 11:41 AM
Volume: 9,029
 

logo
Ajanta Pharma Ltd.
27 Oct 2016
2585.20
0.51%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 18% YoY to | 516 crore (I-direct estimate: | 513 crore) on back of 21% growth in domestic sales to | 158 crore (Idirect estimate: | 155 crore). Export formulation grew 14% to | 345 crore (I-direct estimate: | 339 crore) on a sharp jump in US sales. US sales rose to | 71 crore vs. | 2 crore, | 10 crore in Q2FY16, Q1FY17, respectively. Asia, Africa sales, on the other hand, were muted EBITDA margins declined 157 bps to 33.6% (I-direct estimates: 34.0%) mainly due to forex loss of | 9.84 crore...
Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr
More from Ajanta Pharma Ltd.
Recommended